Mark Sumeray

Mark Sumeray has 32 years’ experience in health care, of which 23 years are in drug development within the pharmaceutical and biotech industries, both in the US and EU. He is currently Chief Medical Officer at Amryt Pharmaceuticals, a Nasdaq listed orphan disease biotech company where he leads the clinical and scientific interactions with global health authorities, including the US Food and Drug Administration and European Medicines Agency. Prior to Amryt he spent five years as Chief Medical Officer at Aegerion Pharmaceuticals, a public orphan disease biotech company based in the US. Earlier in his career he he was at Bristol-Myers Squibb, where he led a large US medical affairs team within the cardiovascular and metabolics area. He spent nine years in clinical practice in the NHS, specialising in cardiovascular surgery and physiology. He earned his medical degree at at UCL (University of London), and also has a BSc in Physiology (UCL), a Master’s degree in Surgery, and is a Fellow of the Royal College of Surgeons.